Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 16 h ago

XBiotech Inc.: MCKENZIE W THORPE amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 18 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

McKenzie W. Thorpe amended a Schedule 13G filing with the SEC covering the Thorpe's stake in XBiotech Inc., according to accession number 0001171843-26-007567. The filing updates the investor's previously reported beneficial ownership position in the clinical-stage biotech. Schedule 13G amendments are typically filed when a passive investor's ownership crosses the 5% threshold or changes materially, making the update a signal of shifting institutional interest in the company. The amended disclosure does not itself alter XBiotech's operations or capital structure. Investors will watch for further 13G or 13D filings to gauge whether Thorpe's position is being built up or trimmed.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

XBiotech Inc., McKenzie W Thorpe